Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at biomarkers in tissue samples from young patients with acute myeloid leukemia previously enrolled on clinical trial POG-9421.
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: proteomic profiling
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Genomic and Proteomic Profiling of Childhood AML|
- Profiling of basal and potentiated phospho-protein networks (PPPNs) using tissue samples [ Designated as safety issue: No ]
- Classification of AML-based signal transduction mechanisms [ Designated as safety issue: No ]
- Correlation of basal and PPPN profiles with specific molecular lesions (e.g., FLT3-ITD, NPM, WT1, c-kit, CEPBα, PASGΔ75, and karyotype) and gene expression profiles. [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||October 2009|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
|Genomic and Proteomic Profiling||Genetic: gene expression analysis Genetic: microarray analysis Genetic: proteomic profiling Other: laboratory biomarker analysis|
- To profile basal and potentiated phospho-protein networks (PPPNs) using tissue samples from pediatric patients with de novo acute myeloid leukemia (AML) previously enrolled on clinical trial POG-9421.
- To classify AML-based signal transduction mechanisms.
- To correlate profiles of basal and PPPNs with specific molecular lesions (e.g., FLT3-ITD, NPM, WT1, c-kit, CEPBα, PASGΔ75, and karyotype) and profiles of gene expression in tumor tissue samples.
OUTLINE: Banked tissue samples are collected for laboratory studies, including phospho-protein signaling and gene expression profiling studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01035307
|Principal Investigator:||Norman J. Lacayo, MD||Stanford University|